Late-breaking clinical trial data for therasphere™ y-90 glass microspheres demonstrates improved survival in primary liver cancer

Marlborough, mass., march 25, 2021 /prnewswire/ -- boston scientific corporation (nyse: bsx) announced positive data from the target study of the therasphere™ y-90 glass microspheres (therasphere) – a type of radioembolization comprised of millions of microscopic glass beads containing radioactive yttrium (y-90) – during a late-breaking clinical trial presentation at the annual scientific meeting for the society of interventional radiology (sir).
BSX Ratings Summary
BSX Quant Ranking